铁超负荷性心肌病的认识与进展

邓英建, 郑小燕, 秦奋, 等. 铁超负荷性心肌病的认识与进展[J]. 临床心血管病杂志, 2019, 35(5): 394-396. doi: 10.13201/j.issn.1001-1439.2019.05.002
引用本文: 邓英建, 郑小燕, 秦奋, 等. 铁超负荷性心肌病的认识与进展[J]. 临床心血管病杂志, 2019, 35(5): 394-396. doi: 10.13201/j.issn.1001-1439.2019.05.002
DENG Yingjian, ZHENG Xiaoyan, QIN Fen, et al. Cognition and advancement of iron overload cardiomyopathy[J]. J Clin Cardiol, 2019, 35(5): 394-396. doi: 10.13201/j.issn.1001-1439.2019.05.002
Citation: DENG Yingjian, ZHENG Xiaoyan, QIN Fen, et al. Cognition and advancement of iron overload cardiomyopathy[J]. J Clin Cardiol, 2019, 35(5): 394-396. doi: 10.13201/j.issn.1001-1439.2019.05.002

铁超负荷性心肌病的认识与进展

详细信息
    通讯作者: 刘启明,E-mail:qimingliu@csu.edu.cn
  • 中图分类号: R542.2

Cognition and advancement of iron overload cardiomyopathy

More Information
  • 铁超负荷性心肌病在临床中较常见且病死率高,是原发性血色病和继发性铁超负荷疾病的主要死亡原因之一。由于早期症状缺乏特异性,铁超负荷性心肌病常被忽视,以至后期治疗效果差。随着心脏磁共振等技术的应用和发展,以及心肌细胞摄取铁离子机制研究的深入,铁超负荷性心肌病的早期诊断及治疗取得满意的效果。现就铁超负荷性心肌病的目前认识和研究进展进行综述。
  • 加载中
  • [1]

    Gulati V, Harikrishnan P, Palaniswamy C, et al.Cardiac involvement in hemochromatosis[J].Cardiol Rev, 2014, 22(2):56-68.

    [2]

    Kremastinos DT, Farmakis D.Iron overload cardiomyopathy in clinical practice[J].Circulation, 2011, 124(20):2253-2263.

    [3]

    Wongjaikam S, Kumfu S, Chattipakorn SC, et al.Current and future treatment strategies for iron overload cardiomyopathy[J].Eur J Pharmacol, 2015, 765:86-93.

    [4]

    Kremastinos DT, Farmakis D, Aessopos A, et al.Beta-thalassemia cardiomyopathy:history, present considerations, and future perspectives[J].Circ Heart Fail, 2010, 3(3):451-458.

    [5]

    Gujja P, Rosing DR, Tripodi DJ, et al.Iron overload cardiomyopathy:better understanding of an increasing disorder[J].J Am Coll Cardiol, 2010, 56(13):1001-1012.

    [6]

    Kumfu S, Chattipakorn SC, Chattipakorn N.T-type and L-type Calcium Channel Blockers for the Treatment of Cardiac Iron Overload:An Update[J].J Cardiovasc Pharmacol, 2017, 70(5):277-283.

    [7]

    Wijarnpreecha K, Kumfu S, Chattipakorn SC, et al.Cardiomyopathy associated with iron overload:how does iron enter myocytes and what are the implications for pharmacological therapy?[J].Hemoglobin, 2015, 39(1):9-17.

    [8]

    Eid R, Arab NT, Greenwood MT.Iron mediated toxicity and programmed cell death:A review and a re-examination of existing paradigms[J].Biochim Biophys Acta, 2017, 1864(2):399-430.

    [9]

    Farmakis D, Triposkiadis F, Lekakis J, et al.Heart failure in haemoglobinopathies:pathophysiology, clinical phenotypes, and management[J].Eur J Heart Fail, 2017, 19(4):479-489.

    [10]

    Schmitt B, Golub RM, Green R.Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level:systematic review for the American College of Physicians[J].Ann Intern Med, 2005, 143(7):522-536.

    [11]

    He T.Cardiovascular magnetic resonance T2* for tissue iron assessment in the heart[J].Quant Imaging Med Surg, 2014, 4(5):407-412.

    [12]

    Buja LM, Roberts WC.Iron in the heart.Etiology and clinical significance[J].Am J Med, 1971, 51(2):209-221.

    [13]

    Brittenham GM.Iron-chelating therapy for transfusional iron overload[J].N Engl J Med, 2011, 364(2):146-156.

    [14]

    Fernandes JL, Loggetto SR, Verissimo MP, et al.A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major[J].Blood, 2016, 128(12):1555-1561.

    [15]

    Kumfu S, Chattipakorn SC, Fucharoen S, et al.Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice[J].Exp Physiol, 2016, 101(4):521-539.

    [16]

    Kremastinos DT, Tsetsos GA, Tsiapras DP, et al.Heart failure in beta thalassemia:a 5-year follow-up study[J].Am J Med, 2001, 111(5):349-354.

  • 加载中
计量
  • 文章访问数:  111
  • PDF下载数:  38
  • 施引文献:  0
出版历程
收稿日期:  2018-10-13

目录